



SCHOLARS
STRATEGY NETWORK

What the PCOS-PMOS Rebrand Tells Us About the State of Women's Health Research

Gabriela Alvarado, University of Wyoming

Chloe E Bird, Tufts University

The announcement last month polycystic ovarian syndrome (PCOS) will be **renamed polyendocrine metabolic ovarian syndrome (PMOS)** was a genuine **milestone**. After 14 years of global collaboration, 22,000 survey responses and workshops spanning every inhabited continent, researchers and patients finally agreed on a name that reflects what the condition actually is: not a quirk of the ovaries, but a complex, multi-system disorder of hormones, metabolism and endocrine function affecting one in eight women worldwide.

For decades, the term *polycystic* had patients and clinicians alike focusing on ovarian cysts, while metabolic dysfunction and insulin resistance went underappreciated and undertreated. Patients report feeling **dismissed, confused and dissatisfied** with their care.